Table I.
Characteristics at cohort entry of the study population∗ for the any fracture analysis
| Individuals with atopic eczema (n = 520,197) | Individuals without atopic eczema (n = 2,568,889) | |
|---|---|---|
| Total person-years of follow-up | 3,118,930 | 14,146,660 |
| Median follow-up time (IQR) | 5.0 (2.0-9.7) | 4.4 (1.7-8.9) |
| Female sex | 303,581 (58.4) | 1,489,176 (58.0) |
| Age band at entry (y) | ||
| 18-39 | 245,469 (47.2) | 1,217,679 (47.4) |
| 40-49 | 69,016 (13.3) | 351,917 (13.7) |
| 50-59 | 63,117 (12.1) | 328,990 (12.8) |
| 60-69 | 60,762 (11.7) | 303,768 (11.8) |
| ≥70 | 81,833 (15.7) | 366,535 (14.3) |
| Quintiles of IMD | ||
| 5 (most deprived) | 74,052 (14.2) | 370,174 (14.4) |
| 4 | 99,223 (19.1) | 489,120 (19.0) |
| 3 | 102,343 (19.7) | 508,442 (19.8) |
| 2 | 119,402 (23.0) | 589,283 (22.9) |
| 1 (least deprived) | 125,177 (24.1) | 611,870 (23.8) |
| Asthma diagnosis | 124,702 (24.0) | 318,410 (12.4) |
| BMI | ||
| Underweight (<18.5 kg/m2) | 37,297 (7.2) | 185,784 (7.2) |
| Normal weight (18.5-24.9 kg/m2) | 170,370 (32.8) | 828,367 (32.2) |
| Overweight (25.0-29.9 kg/m2) | 141,844 (27.3) | 667,277 (26.0) |
| Obese (≥30.0 kg/m2) | 90,971 (17.5) | 393,529 (15.3) |
| Missing | 79,715 (15.3) | 494,073 (19.2) |
| Harmful alcohol use | 14,071 (2.7) | 57,258 (2.2) |
| Smoking status | ||
| Nonsmokers | 263,336 (50.4) | 1,293,912 (50.4) |
| Current or former smokers | 246,022 (46.7) | 1,125,564 (43.8) |
| Missing | 13,839 (2.7) | 149,413 (5.8) |
| High-dose oral glucocorticoid prescription† | 91,587 (17.6) | 191,223 (7.4) |
All values are numbers (percentages), unless otherwise stated.
IQR, Interquartile range.
Note that the study populations for analyses of specific fracture outcomes are similar to those of the study population displayed above (ie, that for the any fracture analysis), but the specific fracture study populations have fewer exclusions because of previous fractures (because individuals were only excluded from these study populations if they had a history of the specific fracture under investigation). Table E2 shows baseline characteristics for the entire eligible study population before exclusion because of the history of previous fracture and is broadly similar to that above (ie, after exclusion of those with a history of previous fracture).
Prednisolone equivalent dose of 20 mg/day or more. Further details on variable definitions can be found in the Methods section in this article’s Online Repository.